Apontis Pharma AG (FRA:APPH) Short-Term Debt: €0.00 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:APPH Apontis Pharma AG FRA:APPH
17 GF Score
Price €11.00
GF Value €10.46
! 7 Warning Signs
View Full Analysis

What is Apontis Pharma AG Short-Term Debt?

Apontis Pharma AG FRA:APPH 17 Short-Term Debt is €0.00 Mil as of Jun. 2025. GuruFocus rates FRA:APPH with a GF Score™ of 17/100 and a GF Value™ of €10.46. The stock has 7 warning signs investors should review.

Apontis Pharma AG's Short-Term Debt for the quarter that ended in Jun. 2025 was €0.00 Mil.

Apontis Pharma AG's annual Short-Term Debt increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€6.02 Mil) but then declined from Dec. 2023 (€6.02 Mil) to Dec. 2024 (€0.00 Mil).

Apontis Pharma AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Apontis Pharma AG Short-Term Debt Related Terms

Apontis Pharma AG Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Apontis Pharma AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apontis Pharma AG Short-Term Debt Chart

Apontis Pharma AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 6.02 0.00

Apontis Pharma AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.02 0.00 0.00 0.00
FRA:APPH
17GF Score
Apontis Pharma AG FRA:APPH
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
Apontis Pharma AG (FRA:APPH) has a Short-Term Debt of €0.00 Mil as of Jun. 2025.
Is Apontis Pharma AG's Short-Term Debt too high?
Apontis Pharma AG's current Short-Term Debt is €0.00 Mil. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's Short-Term Debt compare to ZTS and UTHR?
Apontis Pharma AG's Short-Term Debt of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Apontis Pharma AG's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current Short-Term Debt of €0.00 Mil. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current Short-Term Debt is €0.00 Mil. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current Short-Term Debt is €0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?

Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued. The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.

Key valuation signals for FRA:APPH:

  • Short-Term Debt: €0.00 Mil
  • GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
  • GF Score™: 17/100 with 7 warning signs

No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apontis Pharma AG Business Description

Address Rolf-Schwarz-Schutte-Platz 1, Monheim, BY, DEU, 40789
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score

Get the complete analysis for FRA:APPH

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.00
Price
€10.46
GF Value